Induction of a novel histone deacetylase 1/c-Myc/Mnt/Max complex formation is implicated in parity-induced refractoriness to mammary carcinogenesis

Cancer Science

Volumn 99, Issue 2, 2008, Pages 309-315

  Matsuoka, Yoichiro ^a   Fukamachi, Katsumi ^b   Uehara, Norihisa ^a   Tsuda, Hiroyuki ^b   Tsubura, Airo ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; CYCLIN D2; HISTONE DEACETYLASE 1; MAX PROTEIN; METHYLNITROSOUREA; MNT PROTEIN; MYC PROTEIN; ORNITHINE DECARBOXYLASE; REPRESSOR PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; CANCER INCIDENCE; CELL PROLIFERATION; CHEMICAL CARCINOGENESIS; COMPLEX FORMATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIUM CELL; FEMALE; FIBROBLAST CULTURE; GENE EXPRESSION REGULATION; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE H RAS; PARITY; PRIORITY JOURNAL; PROMOTER REGION; RAT; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TRANSCRIPTION REGULATION; TRANSGENIC RAT; UPREGULATION;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; CELL DIFFERENTIATION; CELL PROLIFERATION; FEMALE; HISTONE DEACETYLASES; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; METHYLNITROSOUREA; PARITY; PREGNANCY; PROTO-ONCOGENE PROTEINS C-MYC; RATS; REPRESSOR PROTEINS;

EID: 38949135139     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00689.x     Document Type: Article

References (46)

1. Kelsey JL, Gammon MD. The epidemiology of breast cancer. CA Cancer J Clin 1991; 41: 146-65.
2. Rosner B, Colditz GA, Willett WC. Reproductive risk factors in a prospective study of breast cancer: The Nurses'Health Study. Am J Epidemiol 1994; 139: 819-35.
3. Medina D, Smith GH. Chemical carcinogen-induced tumorigenesis in parous, involuted mouse mammary glands. J Natl Cancer Inst 1999; 91: 967-9.
4. Guzman RC, Yang J, Rajkumar L, Thordarson G, Chen X, Nandi S. Hormonal prevention of breast cancer: Mimicking the protective effect of pregnancy. Proc Natl Acad Sci USA 1999; 96: 2520-5.
5. Rajkumar L, Guzman RC, Yang J, Thordarson G, Talamantes F, Nandi S. Short-term exposure to pregnancy levels of estrogen prevents mammary carcinogenesis. Proc Natl Acad Sci USA 2001; 98: 11.755-9.
6. Grubbs CJ, Juliana MM, Whitaker LM. Short-term hormone treatment as a chemopreventive method against mammary cancer initiation in rats. Anticancer Res 1988; 8: 113-17.
7. Russo IH, Russo J. Mammary gland neoplasia in long-term rodent studies. Environ Health Perspect 1996; 104: 938-67.
8. Thordarson G, Jin E, Guzman RC, Swanson SM, Nandi S, Talamantes F. Refractoriness to mammary tumorigenesis in parous rats: Is it caused by persistent changes in the hormonal environment or permanent biochemical alterations in the mammary epithelia? Carcinogenesis 1995; 16: 2847-53.
9. Thordarson G, Van Horn K, Guzman RC, Nandi S, Talamantes F. Parous rats regain high susceptibility to chemically induced mammary cancer after treatment with various mammotropic hormones. Carcinogenesis 2001; 22: 1027-33.
10. Sivaraman L, Stephens LC, Markaverich BM et al. Hormone-induced refractoriness to mammary carcinogenesis in Wistar-Furth rats. Carcinogenesis 1998; 19: 1573-81.
11. Medina D, Peterson LE, Moraes R, Gay J. Short-term exposure to estrogen and progesterone induces partial protection against N-nitroso-N-methylurea-induced mammary tumorigenesis in Wistar-Furth rats. Cancer Lett 2001; 169: 1-6.
12. Yang J, Yoshizawa K, Nandi S, Tsubura A. Protective effects of pregnancy and lactation against N-methyl-N-nitrosourea-induced mammary carcinomas in female Lewis rats. Carcinogenesis 1999; 20: 623-8.
13. Schoenenberger CA, Andres AC, Groner B, van der Valk M, LeMeur M, Gerlinger P. Targeted c-myc gene expression in mammary glands of transgenic mice induces mammary tumours with constitutive milk protein gene transcription. EMBO J 1988; 7: 169-75.
14. D'Cruz CM, Gunther EJ, Boxer RB et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 2001; 7: 235-9.
15. Eisenman RN. Deconstructing myc. Genes Dev 2001; 15: 2023-30.
16. Hurlin PJ, Queva C, Eisenman RN. Mnt, a novel Max-interacting protein and Myc antagonist. Curr Top Microbiol Immunol 1997; 224: 115-21.
17. Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 2000; 16: 653-99.
18. Zhou ZQ, Hurlin PJ. The interplay between Mad and Myc in proliferation and differentiation. Trends Cell Biol 2001; 11: S10-14.
19. Ayer DE, Kretzner L, Eisenman RN. Mad: A heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell 1993; 72: 211-22.
20. Hurlin PJ, Queva C, Koskinen PJ et al. Mad3 and Mad4: Novel Max-interacting transcriptional repressors that suppress c-myc dependent transformation and are expressed during neural and epidermal differentiation. EMBO J 1995; 14: 5646-59.
21. Ayer DE. Histone deacetylases: Transcriptional repression with SINers and NuRDs. Trends Cell Biol 1999; 9: 193-8.
22. Hurlin PJ, Huang J. The MAX-interacting transcription factor network. Semin Cancer Biol 2006; 16: 265-74.
23. Bello-Fernandez C, Packham G, Cleveland JL. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci USA 1993; 90: 7804-8.
24. Nilsson JA, Maclean KH, Keller UB, Pendeville H, Baudino TA, Cleveland JL. Mnt loss triggers Myc transcription targets, proliferation, apoptosis, and transformation. Mol Cell Biol 2004; 24: 1560-9.
25. Hurlin PJ, Zhou ZQ, Toyo-oka K et al. Deletion of Mnt leads to disrupted cell cycle control and tumorigenesis. EMBO J 2003; 22: 4584-96.
26. Hurlin PJ, Zhou ZQ, Toyo-Oka K et al. Evidence of mnt-myc antagonism revealed by mnt gene deletion. Cell Cycle 2004; 3: 97-9.
27. Nilsson JA, Cleveland JL. Mnt: Master regulator of the Max network. Cell Cycle 2004; 3: 588-90.
28. Toyo-oka K, Bowen TJ, Hirotsune S et al. Mnt-deficient mammary glands exhibit impaired involution and tumors with characteristics of myc overexpression. Cancer Res 2006; 66: 5565-73.
29. Hamaguchi T, Matsuoka Y, Kawaguchi H et al. Terminal endbuds and acini as the respective major targets for chemical and sporadic carcinogenesis in the mammary glands of human c-Ha-ras protooncogene transgenic rats. Breast Cancer Res Treat 2004; 83: 43-56.
30. Fukamachi K, Matsuoka Y, Kitanaka C, Kuchino Y, Tsuda H. Rat neuronal leucine-rich repeat protein-3: Cloning and regulation of the gene expression. Biochem Biophys Res Comm 2001; 287: 257-63.
31. Fukamachi K, Matsuoka Y, Ohno H, Hamaguchi T, Tsuda H. Neuronal leucine-rich repeat protein-3 amplifies MAPK activation by epidermal growth factor through a carboxyl-terminal region containing endocytosis motifs. J Biol Chem 2002; 277: 43.549-52.
32. Hamaguchi T, Matsuoka Y, Bechberger J et al. Establishment of an apoptosis-sensitive rat mammary carcinoma cell line with a mutation in the DNA-binding region of p53. Cancer Lett 2006; 232: 279-88.
33. Russo J, Hu YF, Silva ID, Russo IH. Cancer risk related to mammary gland structure and development. Microsc Res Tech 2001; 52: 204-23.
34. Medina D, Kittrell FS. p53 function is required for hormone-mediated protection of mouse mammary tumorigenesis. Cancer Res 2003; 63: 6140-3.
35. Sivaraman L, Conneely OM, Medina D, O'Malley BW. p53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis. Proc Natl Acad Sci USA, 2001; 98: 12.379-84.
36. Swanson SM, Whitaker LM, Stockard CR et al. Hormone levels and mammary epithelial cell proliferation in rats treated with a regimen of estradiol and progesterone that mimics the preventive effect of pregnancy against mammary cancer. Anticancer Res 1997; 17: 4639-45.
37. Asamoto M, Ochiya T, Toriyama-Baba H et al. Transgenic rats carrying human c-Ha-ras proto-oncogenes are highly susceptible to N-methyl-N-nitrosourea mammary carcinogenesis. Carcinogenesis 2000; 21: 243-9.
38. Ota T, Asamoto M, Toriyama-Baba H et al. Transgenic rats carrying copies of the human c-Ha-ras proto-oncogene exhibit enhanced susceptibility to N-butyl-N-(4-hydroxybutyl) nitrosamine bladder carcinogenesis. Carcinogenesis 2000; 21: 1391-6.
39. Matsuoka Y, Fukamachi K, Hamaguchi T et al. Rapid emergence of mammary preneoplastic and malignant lesions in human c-Ha-ras proto-oncogene transgenic rats: Possible application for screening of chemopreventive agents. Toxicol Pathol 2003; 31: 632-7.
40. Han BS, Fukamachi K, Takasuka N et al. Inhibitory effects of 17beta-estradiol and 4-n-octylphenol on 7,12-dimethylbenz[a]anthracene-induced mammary tumor development in human c-Ha-ras proto-oncogene transgenic rats. Carcinogenesis 2002; 23: 1209-15.
41. Hann SR, Sloan-Brown K, Spotts GD. Translational activation of the non-AUG-initiated c-myc 1 protein at high cell densities due to methionine deprivation. Genes Dev 1992; 6: 1229-40.
42. Martel C, Lallemand D, Cremisi C. Specific c-myc and max regulation in epithelial cells. Oncogene 1995; 10: 2195-205.
43. Hann SR, Dixit M, Sears RC, Sealy L. The alternatively initiated c-Myc proteins differentially regulate transcription through a noncanonical DNA-binding site. Genes Dev 1994; 8: 2441-52.
44. Fedrowitz M, Kamino K, Loscher W. Significant differences in the effects of magnetic field exposure on 7,12-dimethylbenz (a) anthracene-induced mammary carcinogenesis in two substrains of Sprague-Dawley rats. Cancer Res 2004; 64: 243-51.
45. Cohn SM, Krawisz BR, Dresler SL, Lieberman MW. Induction of replicative DNA synthesis in quiescent human fibroblasts by DNA damaging agents. Proc Natl Acad Sci USA 1984; 81: 4828-32.
46. Uehara N, Unami A, Kiyozuka Y, Shikata N, Oishi Y, Tsubura A. Parous mammary glands exhibit distinct alterations in gene expression and proliferation responsiveness to carcinogenic stimuli in Lewis rats. Oncol Rep 2006; 15: 903-11.